The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and head and neck, per the results published in the journal Cancer.
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
Up to half of obstructive sleep apnea patients taking Zepbound had no symptoms after one year of treatment, averaging 25 ...
Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...
The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback